Your browser doesn't support javascript.
loading
Combined epithelial marker analysis of tumour budding in stage II colorectal cancer.
Slik, Khadija; Blom, Sami; Turkki, Riku; Välimäki, Katja; Kurki, Samu; Mustonen, Harri; Haglund, Caj; Carpén, Olli; Kallioniemi, Olli; Korkeila, Eija; Sundström, Jari; Pellinen, Teijo.
Afiliación
  • Slik K; Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
  • Blom S; Department of Pathology, Misurata Cancer Center, Misurata, Libya.
  • Turkki R; Department of Basic Sciences, Dentistry Faculty, University of Misurata, Misurata, Libya.
  • Välimäki K; Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
  • Kurki S; Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
  • Mustonen H; Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
  • Haglund C; Auria Biobank, University of Turku and Turku University Hospital, Turku, Finland.
  • Carpén O; Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Kallioniemi O; Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Korkeila E; Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland.
  • Sundström J; Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
  • Pellinen T; Auria Biobank, University of Turku and Turku University Hospital, Turku, Finland.
J Pathol Clin Res ; 5(1): 63-78, 2019 01.
Article en En | MEDLINE | ID: mdl-30358171
ABSTRACT
Tumour budding predicts survival of stage II colorectal cancer (CRC) and has been suggested to be associated with epithelial-to-mesenchymal transition (EMT). However, the underlying molecular changes of tumour budding remain poorly understood. Here, we performed multiplex immunohistochemistry (mIHC) to phenotypically profile tumours using known EMT-associated markers E-cadherin (adherence junctions), integrin ß4 (ITGB4; basement membrane), ZO-1 (tight junctions), and pan-cytokeratin. A subpopulation of patients showed high ITGB4 expression in tumour buds, and this coincided with a switch of ITGB4 localisation from the basal membrane of intact epithelium to the cytoplasm of budding cells. Digital image analysis demonstrated that tumour budding with high ITGB4 expression in tissue microarray (TMA) cores correlated with tumour budding assessed from haematoxylin and eosin (H&E) whole sections and independently predicted poor disease-specific survival in two independent stage II CRC cohorts (hazard ratio [HR] = 4.50 (95% confidence interval [CI] = 1.50-13.5), n = 232; HR = 3.52 (95% CI = 1.30-9.53), n = 72). Furthermore, digitally obtained ITGB4-high bud count in random TMA cores was better associated with survival outcome than visual tumour bud count in corresponding H&E-stained samples. In summary, the mIHC-based phenotypic profiling of human tumour tissue shows strong potential for the molecular characterisation of tumour biology and for the discovery of novel prognostic biomarkers.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Biomarcadores de Tumor / Integrina beta4 / Queratinas Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Pathol Clin Res Año: 2019 Tipo del documento: Article País de afiliación: Finlandia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Biomarcadores de Tumor / Integrina beta4 / Queratinas Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Pathol Clin Res Año: 2019 Tipo del documento: Article País de afiliación: Finlandia